Public Employees Retirement System of Ohio Has $66.34 Million Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• The Public Employees Retirement System of Ohio increased its stake in Gilead Sciences by 4.1%, bringing its total holdings to approximately $66.34 million in shares.
• Insider trading activity included Johanna Mercier and CEO Daniel O'Day selling shares, contributing to a total of 82,000 shares worth over $9.39 million sold in the last three months.
• Gilead Sciences reported $2.01 earnings per share for the last quarter, exceeding analyst expectations, and set its FY 2025 guidance at 7.95-8.25 EPS.

Public Employees Retirement System of Ohio increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 598,346 shares of the biopharmaceutical company's stock after purchasing an additional 23,641 shares during the period. Public Employees Retirement System of Ohio's holdings in Gilead Sciences were worth $66,339,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of GILD. Brighton Jones LLC increased its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $215,000. ABLE Financial Group LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $234,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Gilead Sciences in the fourth quarter worth about $104,402,000. Finally, Total Wealth Planning & Management Inc. bought a new position in Gilead Sciences in the 4th quarter valued at approximately $496,000. Institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,390,030. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on GILD shares. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Price Performance

GILD opened at $114.40 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $141.95 billion, a price-to-earnings ratio of 22.79, a P/E/G ratio of 0.76 and a beta of 0.36. The firm's fifty day moving average price is $114.21 and its two-hundred day moving average price is $109.98. Gilead Sciences, Inc. has a 1 year low of $81.83 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the previous year, the company earned $2.01 earnings per share. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.